TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03149302

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Local neck treatment (LNT)
Description: The local neck treatment consists of cervical mobilization and specific therapeutic exercises (30 minutes). The participants will attend 12 individual treatment sessions (2 visits per week for 6 weeks).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LNT plus sensorimotor exercises
Description: The local neck treatment (30 minutes) plus the sensorimotor exercise program (15 minutes). The sensorimotor exercises include cervical joint position sense and oculomotor training. The participants will attend 12 individual treatment sessions (2 visits per week for 6 weeks).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LNT plus balance exercises
Description: The local neck treatment (30 minutes) plus the balance exercise program (15 minutes).The balance program includes with static balance and progress to dynamic balance and gait. The participants will attend 12 individual treatment sessions (2 visits per week for 6 weeks).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LNT plus sensorimotor/balance exercises
Description: The local neck treatment (30 minutes) plus the sensorimotor exercise program (15 minutes) and the balance exercises (15 minutes). The participants will attend 12 individual treatment sessions (2 visits per week for 6 weeks).
Study: NCT02652442

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Centrifugation Distance
Description: To determine optimal distance off-axis, participants were rotated in a darkened rotary chair booth with 1 ear positioned 3.5 cm off-axis and the other ear positioned on-axis for 1 minute. Participants received 5 sessions in a 1-week period. Following a 2-week washout period, participants were rotated in a darkened rotary chair booth with 1 ear positioned 7.0 cm off-axis and the other ear positioned on-axis for 1 minute. Participants received 5 sessions in a 1-week period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Centrifugation Duration
Description: To determine optimal duration, after a two week washout period, participants were rotated off-axis at 3.5 cm (determined to be optimal in Exp 1) for 3 minutes. Participants received 5 sessions in a 1-week period.
Study: NCT03328195

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuro RX Gamma synchronous
Description: Twenty minute treatment, six days per week for 12 weeks

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Twenty minutes, six days per week for 12 weeks with sham device
Study: NCT02652442

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Centrifugation Schedule
Description: To determine optimal schedule, after a two week washout period, participants were rotated off-axis at 3.5 cm (determined to be optimal in Exp 1) for 3 minutes (determined to be optimal in Exp 2). Participants received biweekly sessions for a total of 5 sessions.
Study: NCT02984332

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower limb immobilisation (leg brace)
Study: NCT04124185

Intervention type: DIAGNOSTIC_TEST
Intervention: Ocular assessments
Description: Complete ocular examination, Axial length and corneal curvature, Optical Coherence Tomography, Visual acuity, Contrast sensitivity
Study: NCT01540318

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abdominal Ultrasound (FAST examination)
Description: Use of FAST abdominal ultrasound exam
Study: NCT04072328

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol will be given 0.5 mg/kg bolus initially, and can be administered additionally after a least 30 secs if necessary.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol will be given 0.5 mg/kg bolus initially, and can be administered additionally after a least 30 secs if necessary.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: midazolam with propofol
Study: NCT03148652

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Enhanced Intervention Condition
Description: The intervention incorporates 1) a standard, evidence-based cognitive behavioral therapy-based smoking cessation program, 2) working memory training, and 3) a motivational enhancement component. Working memory training will be administered via the computerized program Cogmed QM. Investigators will be able to monitor participants' progress throughout the study, using the data that the program gathers.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Intervention Condition
Description: The intervention incorporates 1) a standard, evidence-based cognitive behavioral therapy-based smoking cessation program, 2) working memory training, and 3) a motivational enhancement component. Working memory training will be administered via the computerized program Cogmed QM. Investigators will be able to monitor participants' progress throughout the study, using the data that the program gathers.
Study: NCT02257112

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multistage low-energy stimulation
Description: The parameters of the Multistage waveform will be altered and the response of the atria will be recorded.
Study: NCT00666055

Intervention type: DRUG
Intervention: ARV regimen chosen by treating physician
Description: Women may also be naïve to either NNRTI or PIs and initiating their first, second or third HAART regimen (ARVs to be investigated: zidovudine, lamivudine, emtricitabine, abacavir, tenofovir, efavirenz, lopinavir/ritonavir, atazanavir with or without ritonavir).~Provided the ARV regimens contain one or more of the agents under study they may also include new agents such as maraviroc (CCR5 inhibitor), raltegravir (integrase inhibitor) and/or etravirine (NNRTI).

Intervention type: DRUG
Intervention: ARV regimen chosen by treating physician
Description: Women may also be naïve to either NNRTI or PIs and initiating their first, second or third HAART regimen (ARVs to be investigated: zidovudine, lamivudine, emtricitabine, abacavir, tenofovir, efavirenz, lopinavir/ritonavir, atazanavir with or without ritonavir).~Provided the ARV regimens contain one or more of the agents under study they may also include new agents such as maraviroc (CCR5 inhibitor), raltegravir (integrase inhibitor) and/or etravirine (NNRTI).
Study: NCT01167088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoquinone mesylate
Description: 2 tablets to be taken daily upon wakening, with a glass of water and at least one hour before food.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00883649

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hydroeye
Description: 2 Capsules BID
Study: NCT01970007

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zilver Vena Venous Self-Expanding Stent
Description: stenting
Study: NCT03328195

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuro RX Gamma asynchronous
Description: Twenty minutes, six days per week for 12 weeks with sham device
Study: NCT01794897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: Valacyclovir treatment
Description: Patients will have a placebo run-in for two weeks after which they will be evaluated for the variables of interest and then randomized to either VAV or placebo group in a 1:1 proportion. The VAV group will receive 1.5 g Valacyclovir by mouth, twice daily for 16 weeks, after which they will be followed up without VAV for 4 weeks to monitor delayed adverse effects.
Study: NCT00883649

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Inactive Capsule
Description: 2 Capsules BID
Study: NCT01979380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KD101
Description: 200mg (1casule), 600mg (3 capsule), 1000mg (5 capsule), 1400mg (7 capsule) PO, once in the morning

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: PO, once in the morning
Study: NCT01562197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: axitinib
Description: The starting dose of axitinib (AG-013736) is 5 mg BID administered orally with food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib plus Lomustine
Description: Lomustine 90mg/m²
Study: NCT03472768

Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma Haptoglobin Concentration
Description: N/A, comparison of haptoglobin concentration between groups

Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma Haptoglobin Concentration
Description: N/A, comparison of haptoglobin concentration between groups
Study: NCT00923962

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon like peptide-1
Description: 0,1 pmol/kg/min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon like peptide-1
Description: 0,1 pmol/kg/min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon like peptide-1
Description: 0,1 pmol/kg/min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adenosine
Description: 20-40 microgram/minute

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adenosine
Description: 20-40 microgram/minute

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adenosine
Description: 20-40 microgram/minute
Study: NCT04556929

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Intra-operative imaging of 5-ALA fluorescence using ultra-high sensitivity camera
Description: An ultra-high sensitivity camera attached to the side arm of the operative microscope will be used to take images of the anterior, posterior, lateral and inferior walls of the resection cavity on completion of tumour resection.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Intra-operative imaging of 5-ALA fluorescence using in-built operative microscope camera
Description: In-built camera of the operative microscope will be used to take images of the anterior, posterior, lateral and inferior walls of the resection cavity on completion of tumour resection.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Biopsies
Description: Following image capture, biopsies (approx 5x5x5mm size) will be taken from regions of the anterior, posterior, lateral and inferior walls of the resection cavity corresponding to the imaged areas.
Study: NCT04471168

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryo-Auriculotherapy
Description: 3 sessions of cryo-auriculotherapy with device with nitrous oxyde on 10 auricular points at one month intervals.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham comparator
Description: 3 sessions of cryo-auriculotherapy with device without nitrous oxyde on 10 auricular points at one month intervals.
Study: NCT04403841

Intervention type: OTHER
Group type: OTHER
Intervention: patient education and self-management intervention in a low-resource setting on diabetes knowledge and levels of blood glucose control
Description: The intervention consisted group education on type 2 diabetes, including, in addition to usual diabetes care: information on diet, exercise, drug therapy, and adherence

Intervention type: OTHER
Group type: OTHER
Intervention: Usual diabetes care alone
Description: Usual diabetes care was consistent with the ADA guidelines (15) and comprised standard dietary and exercise advice in addition to antidiabetes treatment
Study: NCT03455504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax add in combination with fludarabine, cyratabine and idarubicine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax add in combination with fludarabine, cyratabine and idarubicine
Study: NCT04179760

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCM-AGH
Description: SCM-AGH will be administrated 3 times with 2-week intervals by IV infusion to subjects at Weeks 0, 2 and 4 (Visits 2, 3 and 4).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administrated 3 times with 2-week intervals by IV infusion to subjects at Weeks 0, 2 and 4 (Visits 2, 3 and 4).
Study: NCT05386004

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Birth-Specific Stereogram Cards (BSSC)
Description: Focus on Birth-Specific Stereogram Cards (BSSC) during uterine contractions in latent active and transitional phase
Study: NCT02421640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin+TIL
Description: cisplatin 100mg/m2(every three weeks),D1,D22,D43 of radiotherapy,then TIL infusing following concurrent chemoradiotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: cisplatin 100mg/m2(every three weeks),D1,D22,D43 of radiotherapy only
Study: NCT00583830

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mapatumumab
Description: 30 mg/kg IV (in the vein), on day 1 of each 21 day cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mapatumumab
Description: 10 mg/kg IV (in the vein), on day 1 of each 21 day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 200 mg/m\^2 IV (in the vein), on day 1 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 200 mg/m\^2 IV (in the vein), on day 1 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 200 mg/m\^2 IV (in the vein), on day 1 of each 21 day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: AUC 6.0 mg min/ml IV (in the vein), on day 1 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 6.0 mg min/ml IV (in the vein), on day 1 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 6.0 mg min/ml IV (in the vein), on day 1 of each 21 day cycle
Study: NCT04427410

Intervention type: DIAGNOSTIC_TEST
Intervention: Salivary test
Description: Salivary test for measured of oxytocin levels
Study: NCT06145984

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Positive Fantasizing
Description: In a two-hour training session by a professional trainer, participants get familiar with the positive fantasizing technique. Participants receive psycho-education about the role of dysfunctional beliefs. The positive fantasizing technique starts with identifying dysfunctional beliefs and schema and subsequently fantasize about a positive fantasy belief. Participants are guided by the professional using imagery and experiencing thoughts and feelings that would be elicited when using their fantasy belief as if in an ideal world. After using imagery techniques, participants are asked, with help of the professional, to reflect on their experience during the fantasizing exercise and to think of how they could implement this fantasy belief more in their daily life, by adapting their fantasy belief into a more practical belief. After the training, participants are asked to perform one exercise per day using the fantasizing technique using a mobile application for six days in total.
Study: NCT01794897

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Patients will have a placebo run-in for two weeks after which they will be evaluated for the variables of interest and then randomized to either VAV or placebo group in a 1:1 proportion. Subjects in the placebo arm will receive placebo for 16 weeks, after which they will be followed up without placebo for 4 weeks to monitor delayed adverse effects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo comparator
Description: Patients will have a placebo run-in for two weeks after which they will be evaluated for the variables of interest and then randomized to either VAV or placebo group in a 1:1 proportion. Subjects in the placebo arm will receive placebo for 16 weeks, after which they will be followed up without placebo for 4 weeks to monitor delayed adverse effects.
Study: NCT01944176

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: simvastatin, placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin, placebo
Study: NCT03373773

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Foley catheter removal
Description: After reinsertion of the Foley catheter, both groups of women will be given instructions on urinary catheter and bag management, this will be done by an RN as per standard protocol. Prior to discharge, every subject from the home removal group as well as their significant other/caregiver/family member will receive a standardized education session and written and illustrated instructions on Foley catheter removal from RN, per standard protocol. They will be provided with the syringe for catheter removal, urine collection pan, and a diary to record their voiding quality and quantity. Both groups of women will have the catheter removal in 2 days.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Foley catheter removal
Description: After reinsertion of the Foley catheter, both groups of women will be given instructions on urinary catheter and bag management, this will be done by an RN as per standard protocol. Prior to discharge, every subject from the home removal group as well as their significant other/caregiver/family member will receive a standardized education session and written and illustrated instructions on Foley catheter removal from RN, per standard protocol. They will be provided with the syringe for catheter removal, urine collection pan, and a diary to record their voiding quality and quantity. Both groups of women will have the catheter removal in 2 days.
Study: NCT00351975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03344861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Porfimer Sodium
Description: Porfimer sodium (Photofrin®) will be injected intravenously at a dose of 2 mg/kg.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fiber optic
Description: After injection of porfimer sodium (Photofrin®), a flexible bronchoscopy with navigation guidance will be performed to confirm the location and the size of the lesion with the use of radial probe endobronchial ultrasonography (REBUS). An optical fiber diffuser length matching the tumor length will be placed in the lesion or adjacent to the lesion under fluoroscopy guidance. After the placement of the optical fiber, the laser light will be applied at a dose of 200 J/cm of diffuser length.
Study: NCT04488068

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham Magnetic stimulation
Description: Sham Magnetic stimulation for comparison.
Study: NCT03128554

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention with Training and Materials
Description: Peer-Led Continuing Medical Education Session and Provider/Patient Handouts
Study: NCT03131011

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UV fluorescent ink
Description: The use of UV tattoo ink results in a tattoo that is visible only under an ultraviolet light. Conventional black tattoo ink is replaced with UV ink for the application of radiotherapy dot tattoos. Handheld UV flashlights are used to make the tattoos visible for use during radiotherapy treatment set-up.
Study: NCT04200664

Intervention type: DIAGNOSTIC_TEST
Intervention: Hearing assessment
Description: All study participants will undergo hearing tests, including hearing-specific questionnaires

Intervention type: DIAGNOSTIC_TEST
Intervention: Hearing assessment
Description: All study participants will undergo hearing tests, including hearing-specific questionnaires
Study: NCT03658616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WO3970
Description: Application of cream to each axilla

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (WO3988)
Description: Application of cream to each axilla
Study: NCT01446497

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimonidine/Timolol mixed combination
Description: Twice per day, 1 drop at each time

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol
Description: Twice per day, 1 drop at each time
Study: NCT03953001

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adminstration Technique using Buzzy external distractor
Description: External application of Buzzy distractor during administration of dental anesthetic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% Lidocaine with 1:50,000 epinephrine
Description: Local Dental anesthetic infiltration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% Lidocaine with 1:50,000 epinephrine
Description: Local Dental anesthetic infiltration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Anesthetic
Description: 20% Benzocaine gel was applied on the area of infiltration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Anesthetic
Description: 20% Benzocaine gel was applied on the area of infiltration
Study: NCT04200664

Intervention type: DIAGNOSTIC_TEST
Intervention: Hearing assessment
Description: All study participants will undergo hearing tests, including hearing-specific questionnaires

Intervention type: DIAGNOSTIC_TEST
Intervention: Vestibular/balance assessment
Description: Siderosis group participants will undergo vestibular/balance tests, including gait assessment and balance-specific questionnaires

Intervention type: OTHER
Intervention: Quality of life assessment
Description: All study participants will be asked to complete a set of quality of life questionnaires

Intervention type: OTHER
Intervention: Quality of life assessment
Description: All study participants will be asked to complete a set of quality of life questionnaires

Intervention type: OTHER
Intervention: Quality of life assessment
Description: All study participants will be asked to complete a set of quality of life questionnaires
Study: NCT04144335

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: N-803 and bNAbs
Description: Treatment will consist of N-803, VRC07-523LS, PGT121, and haNK, with N-803 given for 3 cycles of 9 weeks/cycle. N-803 will be given every 3 weeks (3 doses/cycle) and bNAbs will be given every 9 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N-803 and bNAbs
Description: Treatment will consist of N-803, VRC07-523LS, PGT121, and haNK, with N-803 given for 3 cycles of 9 weeks/cycle. N-803 will be given every 3 weeks (3 doses/cycle) and bNAbs will be given every 9 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: haNK™ Cells
Description: Treatment will consist of N-803, VRC07-523LS, PGT121, and haNK, with N-803 given for 3 cycles of 9 weeks/cycle. N-803 will be given every 3 weeks (3 doses/cycle), bNAbs will be given every 9 weeks, and haNK cells administered on the same day as each infusion of N-803.
Study: NCT00832169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1386
Description: 1 dose of oral solution